Decitabine - AILBRY - Article Search

Results for 'Decitabine' :

Decitabine improves patient outcomes in myelodysplastic syndromes

Publication Year: 2006

DOI: https://doi.org/10.1002/cncr.21792

Abstract:

Authors:
- Hagop M. Kantarjian
- Jean‐Pierre J. Issa
- C Rosenfeld
- John M. Bennett
- Maher Albitar
- John F. DiPersio
- Virginia M. Klimek
- James L. Slack
- Carlos de Castro Lozano
- Farhad Ravandi
- Richard E. Helmer
- Lanlan Shen
- Stephen D. Nimer
- Richard D. Leavitt
- Azra Raza
- Hussain I. Saba
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

Publication Year: 2008

DOI: https://doi.org/10.1002/ijc.23607

Abstract:

Authors:
- Carlo Stresemann
- Frank Lyko
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Publication Year: 2018

DOI: https://doi.org/10.1182/blood-2018-08-868752

Abstract:

Authors:
- Courtney D. DiNardo
- Keith W. Pratz
- Vinod Pullarkat
- Brian A. Jonas
- Martha Arellano
- Pamela S. Becker
- Olga Frankfurt
- Marina Konopleva
- Andrew H. Wei
- Hagop M. Kantarjian
- Tu Xu
- Wan-Jen Hong
- Brenda Chyla
- Jalaja Potluri
- Daniel A. Pollyea
- Anthony Letai
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Publication Year: 2016

DOI: https://doi.org/10.1056/nejmoa1605949

Abstract:

Authors:
- John S. Welch
- Allegra A. Petti
- Christopher A. Miller
- Catrina C. Fronick
- Michelle D. O’Laughlin
- Robert S. Fulton
- Richard K. Wilson
- Jack Baty
- Eric J. Duncavage
- Bevan Tandon
- Yi-Shan Lee
- Lukas D. Wartman
- Geoffrey L. Uy
- Armin Ghobadi
- Michael H. Tomasson
- Iskra Pusic
- Rizwan Romee
- Todd A. Fehniger
- Keith Stockerl‐Goldstein
- Ravi Vij
- Stephen T. Oh
- Camille N. Abboud
- Amanda F. Cashen
- Mark A. Schroeder
- Meagan A. Jacoby
- Sharon E. Heath
- Kierstin Luber
- Megan Janke
- Andrew Hantel
- Niloufer Khan
- Madina Sukhanova
- Randall W. Knoebel
- Wendy Stock
- Timothy A. Graubert
- Matthew J. Walter
- Peter Westervelt
- Daniel C. Link
- John F. DiPersio
- Timothy J. Ley
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Publication Year: 2012

DOI: https://doi.org/10.1200/jco.2011.38.9429

Abstract:

Authors:
- Hagop M. Kantarjian
- Xavier Thomas
- Anna Dmoszyńska
- Agnieszka Wierzbowska
- Grzegorz Mazur
- Jiří Mayer
- Jyh-Pyng Gau
- Wen‐Chien Chou
- Rena Buckstein
- Jaroslav Čermák
- Ching-Yuan Kuo
- Albert Oriol
- Farhad Ravandi
- Stefan Faderl
- Jacques Delaunay
- Daniel Lysák
- Mark D. Minden
- Christopher Arthur
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

Publication Year: 2003

DOI: https://doi.org/10.1182/blood-2003-03-0687

Abstract:

Authors:
- Jean‐Pierre J. Issa
- Guillermo Garcia‐Manero
- Francis J. Giles
- Rajan K. Mannari
- Deborah A. Thomas
- Stefan Faderl
- Emel Bayar
- John F. Lyons
- C Rosenfeld
- Jorge E. Cortés
- Hagop M. Kantarjian
Evolution of decitabine development

Publication Year: 2008

DOI: https://doi.org/10.1002/cncr.23463

Abstract:

Authors:
- Elias Jabbour
- Jean‐Pierre J. Issa
- Guillermo Garcia‐Manero
- Hagop M. Kantarjian
Concise Drug Review: Azacitidine and Decitabine

Publication Year: 2013

DOI: https://doi.org/10.1634/theoncologist.2012-0465

Abstract:

Authors:
- Ellen J. B. Derissen
- Jos H. Beijnen
- Jan H.M. Schellens
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment

Publication Year: 2002

DOI: https://doi.org/10.1182/blood.v100.8.2957

Abstract:

Authors:
- Michael Daskalakis
- TuDung T. Nguyen
- Carvell T. Nguyen
- Per Guldberg
- Gabriele Köhler
- Pierre W. Wijermans
- Peter A. Jones
- Michael Lübbert
Clinical response and <i>miR-29b</i> predictive significance in older AML patients treated with a 10-day schedule of decitabine

Publication Year: 2010

DOI: https://doi.org/10.1073/pnas.1002650107

Abstract:

Authors:
- William Blum
- Ramiro Garzon
- Rebecca B. Klisovic
- Sebastian Schwind
- Alison Walker
- Susan M. Geyer
- Shujun Liu
- Violaine Havelange
- Heiko Becker
- Larry J. Schaaf
- Jon Mickle
- Hollie Devine
- Cheryl Kefauver
- Steven M. Devine
- Kenneth K. Chan
- Nyla A. Heerema
- Clara D. Bloomfield
- Michael R. Grever
- John C. Byrd
- Miguel A. Villalona‐Calero
- Carlo M. Croce
- Guido Marcucci
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

Publication Year: 2009

DOI: https://doi.org/10.1200/jco.2009.23.9178

Abstract:

Authors:
- Amanda F. Cashen
- Gary J. Schiller
- Margaret O’Donnell
- John F. DiPersio
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Publication Year: 2006

DOI: https://doi.org/10.1182/blood-2006-05-021162

Abstract:

Authors:
- Hagop M. Kantarjian
- Yasuhiro Oki
- Guillermo Garcia‐Manero
- Xuelin Huang
- Susan O’Brien
- Jorge E. Cortés
- Stefan Faderl
- Carlos E. Bueso‐Ramos
- Farhad Ravandi
- Zeev Estrov
- Alessandra Ferrajoli
- William G. Wierda
- Jianqin Shan
- Jan Davis
- Francis J. Giles
- Hussain I. Saba
- Jean‐Pierre J. Issa
A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

Publication Year: 2010

DOI: https://doi.org/10.1371/journal.pone.0009001

Abstract:

Authors:
- Paul W. Hollenbach
- Aaron Nguyen
- Helen Brady
- Michelle M. Williams
- Yuhong Ning
- Normand Richard
- Leslie A. Krushel
- Sharon L. Aukerman
- Carla Heise
- Kyle J. MacBeth
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia

Publication Year: 2007

DOI: https://doi.org/10.1200/jco.2006.09.4169

Abstract:

Authors:
- William Blum
- Rebecca B. Klisovic
- Bjoern Hackanson
- Zhongfa Liu
- Shujun Liu
- Hollie Devine
- Tamara Vukosavljevic
- Lenguyen Huynh
- Gerard Lozanski
- Cheryl Kefauver
- Christoph Plass
- Steven M. Devine
- Nyla A. Heerema
- Anthony J. Murgo
- Kenneth K. Chan
- Michael R. Grever
- John C. Byrd
- Guido Marcucci
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

Publication Year: 2010

DOI: https://doi.org/10.1002/cncr.25247

Abstract:

Authors:
- Elias Jabbour
- Guillermo Garcia‐Manero
- Nicolas Batty
- Jenny Shan
- Susan O’Brien
- Jorge E. Cortés
- Farhad Ravandi
- Jean‐Pierre J. Issa
- Hagop M. Kantarjian

Found 18041 results in 0.056 seconds

What is Boolean Searches

Including any of the words AND, OR, or NOT in any of your searches will enable boolean search. Those words must be UPPERCASE. You can use this in all searches, including using the search parameter, and using search filters.

This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks. Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and stop-word removal (be sure to use double quotation marks — "). Using parentheses will specify order of operations for the boolean operators. Words that are not separated by one of the boolean operators will be interpreted as AND.

Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard and fuzzy searches using *, ? or ~ are not allowed; these characters will be removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as described above, including stemming and removal of stop words.

Example Search

Search for works that mention "elmo" and "sesame street", but not the words "cookie" or "monster":

AILBRY - Article Search

Results for 'Decitabine' :

Decitabine improves patient outcomes in myelodysplastic syndromes

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

Evolution of decitabine development

Concise Drug Review: Azacitidine and Decitabine

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment

Clinical response and <i>miR-29b</i> predictive significance in older AML patients treated with a 10-day schedule of decitabine

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

What is Boolean Searches

Example Search